Cinryze received FDA approval for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema.
With this agreement, ViroPharma has received exclusive license to C1 esterase inhibition and to the hereditary angioedema (HAE) indication, along with three additional orphan indications.
As per the terms of the agreement, ViroPharma is responsible to pay a sum of $83m commencing with an upfront payment of $9m and total potential future milestone payments of $74m to Halozyme dependent upon the achievement of clinical and regulatory targets, plus a 10% royalty on future sales of the combination of Cinryze with rHuPH20.
ViroPharma will fund all development and commercialization expenses for the program.
Halozyme president and CEO Gregory Frost said Halozyme’s rHuPH20 enzyme may facilitate the subcutaneous administration and absorption of a broad range of pharmaceuticals and biologics, including plasma-derived proteins such as Cinryze.
A combination formulation of Cinryze with rHuPH20 for subcutaneous, or under the skin, administration is expected to enter clinical trials by the end of the year.